|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.150 GBX | 0.00% |
|
-3.08% | -55.63% |
| 29/05 | Poolbeg Pharma PLC - Shareholder/Analyst Call | |
| 27/05 | Poolbeg Pharma shares up after US FDA orphan drug designation | AN |
Company Valuation: Poolbeg Pharma PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 47.5 | 30.25 | 45.25 | 35.5 | 21.96 | - |
| Change | - | -36.32% | 49.59% | -21.55% | -38.14% | - |
| Enterprise Value (EV) 1 | 47.5 | 14.06 | 33.08 | 27.68 | 14.79 | 20.04 |
| Change | - | -70.41% | 135.32% | -16.33% | -46.55% | 35.44% |
| P/E ratio | -12.8x | -6.44x | -11.5x | -6.12x | -3.18x | -3.8x |
| PBR | - | 1.65x | 3.02x | 3.83x | 2.63x | 7.88x |
| PEG | - | -0.2x | 0.7x | -0.1x | 0.2x | 0.2x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | -2.83x | -7.1x | -4.61x | -2.74x | -3.58x |
| EV / EBIT | - | -2.82x | -7.06x | -4.53x | -2.56x | -3.41x |
| EV / FCF | - | -2.83x | -7.26x | -5.8x | -2.9x | -3.71x |
| FCF Yield | - | -35.3% | -13.8% | -17.3% | -34.5% | -27% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0074 | -0.0094 | -0.0079 | -0.0116 | -0.0099 | -0.0083 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | - | -4.96 | -4.66 | -5.997 | -5.4 | -5.6 |
| EBIT 1 | - | -4.986 | -4.686 | -6.111 | -5.775 | -5.875 |
| Net income 1 | -2.336 | -4.686 | -3.931 | -5.79 | -5.94 | -5.75 |
| Net Debt 1 | - | -16.19 | -12.17 | -7.824 | -7.168 | -1.926 |
| Reference price 2 | 0.0950 | 0.0605 | 0.0905 | 0.0710 | 0.0315 | 0.0315 |
| Nbr of stocks (in thousands) | 5,00,000 | 5,00,000 | 5,00,000 | 5,00,000 | 6,97,200 | - |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | - | - |
1GBP in Million2GBP
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.18x | - | -2.74x | - | 2.98Cr | ||
| 47.59x | 8.06x | 35.91x | -.--% | 3.33TCr | ||
| 17.08x | 4.19x | 11.45x | 1.7% | 2.78TCr | ||
| -23.67x | 5.91x | -9.65x | -.--% | 2.75TCr | ||
| -57.55x | - | -57.84x | -.--% | 1.84TCr | ||
| -18.06x | 40.28x | -19.81x | -.--% | 1.83TCr | ||
| 24.56x | 4.3x | 12.49x | -.--% | 1.34TCr | ||
| 13.28x | 2.61x | 7.36x | -.--% | 1.32TCr | ||
| 1970.31x | 25.43x | 290.64x | -.--% | 1.26TCr | ||
| 19.13x | 4.6x | 13.23x | -.--% | 1.2TCr | ||
| Average | 198.95x | 11.92x | 28.10x | 0.19% | 1.77TCr | |
| Weighted average by Cap. | 144.36x | 11.08x | 22.06x | 0.27% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- POLB Stock
- Valuation Poolbeg Pharma PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition